Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan

To date, efficacy data on botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia (CD) previously treated with botulinum toxin type A in a large population are lacking; thus, we aimed to evaluate type B efficacy in this patient population. In a post-marketing observational co...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ryuji Kaji, Akira Endo, Michiko Sugawara, Mika Ishii
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Cervical dystonia Post-marketing observational study Botulinum toxin type A Botulinum toxin type B Toronto Western Spasmodic Torticollis Rating Scale Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/160c2045227b4c5fb2abdf6b88488561
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:160c2045227b4c5fb2abdf6b88488561
record_format	dspace
spelling	oai:doaj.org-article:160c2045227b4c5fb2abdf6b884885612021-11-24T04:32:29ZEfficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan2405-650210.1016/j.ensci.2021.100374https://doaj.org/article/160c2045227b4c5fb2abdf6b884885612021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2405650221000678https://doaj.org/toc/2405-6502To date, efficacy data on botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia (CD) previously treated with botulinum toxin type A in a large population are lacking; thus, we aimed to evaluate type B efficacy in this patient population. In a post-marketing observational cohort study, 150 patients previously treated with botulinum toxin type A were enrolled, of whom 138 were followed up for 1 year after the initial type B injection. Final observation data were available for 122 patients. Efficacy was evaluated using the Toronto Western Spasmodic Torticollis Rating Scale. Total score improved from 39.9 at baseline to 34.3 at 4 weeks after the first injection, and pain score improved from 8.9 to 7.9. Improvements were maintained through six further injections in two subpopulations: patients who showed resistance to botulinum toxin type A and patients who were not type A resistant but switched to type B. For a number of patients, even low doses (<5000 units) of botulinum toxin type B demonstrated efficacy. These findings support the efficacy of botulinum toxin type B in clinical settings for the management of CD symptoms, including pain, even at low doses, regardless of the patient's botulinum toxin type A resistance status.Ryuji KajiAkira EndoMichiko SugawaraMika IshiiElsevierarticleCervical dystoniaPost-marketing observational studyBotulinum toxin type ABotulinum toxin type BToronto Western Spasmodic Torticollis Rating ScaleNeurology. Diseases of the nervous systemRC346-429ENeNeurologicalSci, Vol 25, Iss , Pp 100374- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cervical dystonia Post-marketing observational study Botulinum toxin type A Botulinum toxin type B Toronto Western Spasmodic Torticollis Rating Scale Neurology. Diseases of the nervous system RC346-429
spellingShingle	Cervical dystonia Post-marketing observational study Botulinum toxin type A Botulinum toxin type B Toronto Western Spasmodic Torticollis Rating Scale Neurology. Diseases of the nervous system RC346-429 Ryuji Kaji Akira Endo Michiko Sugawara Mika Ishii Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan
description	To date, efficacy data on botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia (CD) previously treated with botulinum toxin type A in a large population are lacking; thus, we aimed to evaluate type B efficacy in this patient population. In a post-marketing observational cohort study, 150 patients previously treated with botulinum toxin type A were enrolled, of whom 138 were followed up for 1 year after the initial type B injection. Final observation data were available for 122 patients. Efficacy was evaluated using the Toronto Western Spasmodic Torticollis Rating Scale. Total score improved from 39.9 at baseline to 34.3 at 4 weeks after the first injection, and pain score improved from 8.9 to 7.9. Improvements were maintained through six further injections in two subpopulations: patients who showed resistance to botulinum toxin type A and patients who were not type A resistant but switched to type B. For a number of patients, even low doses (<5000 units) of botulinum toxin type B demonstrated efficacy. These findings support the efficacy of botulinum toxin type B in clinical settings for the management of CD symptoms, including pain, even at low doses, regardless of the patient's botulinum toxin type A resistance status.
format	article
author	Ryuji Kaji Akira Endo Michiko Sugawara Mika Ishii
author_facet	Ryuji Kaji Akira Endo Michiko Sugawara Mika Ishii
author_sort	Ryuji Kaji
title	Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan
title_short	Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan
title_full	Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan
title_fullStr	Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan
title_full_unstemmed	Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan
title_sort	efficacy of botulinum toxin type b (rimabotulinumtoxinb) in patients with cervical dystonia previously treated with botulinum toxin type a: a post-marketing observational study in japan
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/160c2045227b4c5fb2abdf6b88488561
work_keys_str_mv	AT ryujikaji efficacyofbotulinumtoxintypebrimabotulinumtoxinbinpatientswithcervicaldystoniapreviouslytreatedwithbotulinumtoxintypeaapostmarketingobservationalstudyinjapan AT akiraendo efficacyofbotulinumtoxintypebrimabotulinumtoxinbinpatientswithcervicaldystoniapreviouslytreatedwithbotulinumtoxintypeaapostmarketingobservationalstudyinjapan AT michikosugawara efficacyofbotulinumtoxintypebrimabotulinumtoxinbinpatientswithcervicaldystoniapreviouslytreatedwithbotulinumtoxintypeaapostmarketingobservationalstudyinjapan AT mikaishii efficacyofbotulinumtoxintypebrimabotulinumtoxinbinpatientswithcervicaldystoniapreviouslytreatedwithbotulinumtoxintypeaapostmarketingobservationalstudyinjapan
_version_	1718415960432443392

Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan

Ejemplares similares